|
Title
|
Status
|
|
|
Recruiting
in 1 of 1 locations
|
|
Angiogenesis increases in higher risk MDS patients and those with proliferative CMML. Angiogenesis is associated with increased risk of leukemic transformation and poorer prognoses. Low dose chemotherapy may have anti-angiogenic properties by targetting the genetically stable endothelial cells. Lenalidomide has been recently shown to be highly effective as monotherapy in low/low-intermediate risk MDS, particularly in the subgroup harboring a 5q- deletion. Lenalidomide has not been well studied in higher risk MDS although there are some reports of lenalidomide's efficacy in RAEB-T and AML. One potential mode of action of lenalidomide is inhibition of angiogenesis. The investigators hypothesize that by combining lenalidomide with low dose melphalan in higher risk MDS the investigators will more effectively block angiogenesis and achieve responses or hematologic improvement in MDS.
|
|
|
Recruiting
in 3 of 3 locations
|
|
The purpose of this study is to determine if lenalidomide (Revlimid®) is safe and effective as a maintenance therapy at improving further the quality of the response you achieved with your last therapy and at prolonging the duration of your response. This study will compare the effects (good and bad) of lenalidomide with the dummy drug.
|
|
|
Recruiting
in 1 of 1 locations
|
|
The purpose of this study is to determine if Revlimid will help maintain patients with acute myeloid leukemia in remission.
|
|
|
Recruiting
in 2 of 2 locations
|
|
The purpose of this study is to determine the safety and efficacy of lenalidomide as a first
line therapy in treating patients with B-cell Chronic Lymphocytic Leukemia. This study will
compare the effects (good and bad) of lenalidomide with chlorambucil.
|
|
|
Recruiting
in 13 of 16 locations
|
|
The purpose of this study is to compare the safety and efficacy of Lenalidomide plus low dose dexamethasone to that of the combination of melphalan, prednisone and thalidomide.
|
|
|
Recruiting
in 2 of 2 locations
|
|
The purpose of this study is to determine the safety and effectiveness of different dose
regimen of lenalidomide in patients with relapsed or refractory chronic lymphocytic
leukemia.
|
|
|
Recruiting
in 1 of 1 locations
|
|
This is a phase II, non-randomized, single institution study in symptomatic, previously untreated CLL patients. All patients will receive the study drug, lenalidomide, given PO daily continuously on a 28 day cycle at the starting dose level of either 2.5 mgs or 5 mgs with dose escalations to a target dose of 25mg daily. Oral dexamethasone at 12 mg PO daily will be administered on days 1-7, 14 and 21 of each cycle. Patients will be treated with lenalidomide and dexamethasone to 2 cycles past CR or to a maximum of 18 cycles. Primary endpoint is response.
|
|
|
Recruiting
in 4 of 4 locations
|
|
T-cell Non-Hodgkin's lymphomas are a group of cancers that are usually treated with
chemotherapy, radiation therapy, or occasionally surgery. T-cell lymphomas are relatively
uncommon and therefore not well studied. Treatment approaches are patterned after the more
common B-cell lymphomas. T-cell lymphomas are more likely to relapse following standard
therapy than are B-cell lymphomas. New therapies are needed for T-cell lymphomas. In this
study, we will administer the drug called lenalidomide as a pill to patients with T-cell
lymphoma. The goals are to determine if the drug can induce regression of the cancer, and to
determine if the treatment is well tolerated in this patient group. This study will take
place at six cancer centres across Canada.
|
